NCT02416206View on ClinicalTrials.gov

High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

April 27, 2015

Primary Completion Date

March 26, 2020

Study Completion Date

April 21, 2021

Conditions
Multiple Myeloma
Interventions
DRUG

BeEAM

BeEAM

Trial Locations (1)

30342

Blood and Marrow Transplant Group of Georgia, Atlanta

All Listed Sponsors
collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

Northside Hospital, Inc.

OTHER

NCT02416206 - High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma | Biotech Hunter | Biotech Hunter